Genetically determined differences in P-glycoprotein function: Implications for disease risk

Toxicology

Volumn 181-182, Issue , 2002, Pages 299-303

  Fromm, Martin F ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Genetic polymorphism; HIV; P glycoprotein; Renal cell carcinoma; Ulcerative colitis

Indexed keywords

DIGOXIN; GENE PRODUCT; GLYCOPROTEIN P; MUTANT PROTEIN;

BIOAVAILABILITY; BLOOD CELL; BLOOD LEVEL; CHEMOTHERAPY; DETOXIFICATION; DRUG RESISTANCE; ENTERITIS; GENE; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE; KIDNEY; KIDNEY CARCINOMA; LIVER; MULTIDRUG RESISTANCE; POPULATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TUMOR; ULCERATIVE COLITIS;

EID: 18144437085     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(02)00297-4     Document Type: Article

References (27)

1. Alsenz J., Steffen H., Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Coco-2 cell monolayers. Pharm. Res. 15:1998;423-428.
2. Ameyaw M.-M., Regateiro F., Li T., Liu X., Tariq M., Mobarek A., Thornton N., Folayan G.O., Githang'a J., Indalo A., Ofori-Adjei D., Price-Evans D., McLeod H.L. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 11:2001;217-221.
3. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., Schäffeler E., Eichelbaum M., Brinkmann U., Roots I. Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR1 gene in Caucasians. Clin. Pharmacol. Ther. 69:2001;169-174.
4. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J., Wilkinson G.R., Kim R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:2000;655-660.
5. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA. 86:1989;695-698.
6. Dianda L., Hanby A.M., Wright N.A., Sebesteny A., Hayday A.C., Owen M.J. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am. J. Pathol. 150:1997;91-97.
7. Fromm M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38:2000;69-74.
8. Fromm M.F., Kim R.B., Stein C.M., Wilkinson G.R., Roden D.M. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 99:1999;552-557.
9. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.-P., von Richter O., Zundler J., Kroemer H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:1999;147-153.
10. Hermiston M.L., Gordon J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 270:1995;1203-1207.
11. + natural killer cells. Pharmacogenetics. 11:2001;1-6.
12. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA. 97:2000;3473-3478.
13. Huisman M.T., Smit J.W., Schinkel A.H. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. 14:2000;237-242.
14. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455:1976;152-162.
15. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
16. Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 83:1994;2451-2458.
17. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V., Pastan I., Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 37:1998;3594-3601.
18. Lee C.G., Ramachandra M., Jeang K.T., Martin M.A., Pastan I., Gottesman M.M. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 14:2000;516-522.
19. Longuemaux S., Delomenie C., Gallou C., Mejean A., Vincent-Viry M., Bouvier R., Droz D., Krishnamoorthy R., Galteau M.M., Junien C., Beroud C., Dupret J.M. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res. 59:1999;2903-2908.
20. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin R., Brown M.B., Guo W., Rossi S.J., Benet L.Z., Watkins P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:1997;248-260.
21. Mickley L.A., Lee J.S., Weng Z., Zhan Z., Alvarez M., Wilson W., Bates S.E., Fojo T. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines and human tumors. Blood. 91:1998;1749-1756.
22. Panwala C.M., Jones J.C., Viney J.L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161:1998;5733-5744.
23. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94) an HIV protease inhibitor. Pharm. Res. 16:1999;1206-1212.
24. Schaeffeler, E., Eichelbaum, M., Brinkmann, U., Penger, A., Asante-Poku, S., Zanger, U., Schwab, M., 2001. Over-representation of the high expressor genotype of the C3435T MDR1 gene polymorphism in West Africans and African Americans: Consequences for drug treatment. Lancet, 358, 383-384.
25. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297:2001;1137-1143.
26. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA. 84:1987;7735-7738.
27. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., Fritz P., von R.O., Warzok R., Hachenberg T., Kauffmann H.M., Schrenk D., Terhaag B., Kroemer H.K., Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68:2000;345-355.